By Johnny Rice, Benzinga

John Alam, MD - Chief Executive Officer of CervoMed Inc. (NASDAQ: CRVO), was recently a guest on Benzinga’s All-Access.

CervoMed is a clinical-stage company dedicated to the development and commercialization of targeted drug treatments for neurodegenerative diseases with a focus on the early stages of the disease process.

Mr. Alam spoke of the promising topline results from the ongoing phase 2b trial of its lead drug candidate.

Watch the full interview here:

Featured photo by JD Mason on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.

Benzinga

+1 877-440-9464

info@benzinga.com

http://www.benzinga.com

View source version on newsdirect.com: https://newsdirect.com/news/clinical-trial-results-show-positive-signs-for-potential-new-dementia-treatment-609208791

This press release is distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Clinical Trial Results Show Positive Signs For Potential New Dementia Treatment.